What is the recommended management for acute myeloid leukemia with FLT3 mutation?

Management of FLT3-Mutated Acute Myeloid Leukemia

Frontline Therapy for Fit Patients

For newly diagnosed FLT3-mutated AML in patients eligible for intensive chemotherapy, the standard of care is 7+3 induction (cytarabine 200 mg/m²/day continuous infusion × 7 days plus daunorubicin 60 mg/m² × 3 days) with midostaurin 50 mg orally twice daily on days 8–21. 1, 2

Induction Regimen Details

• Cytarabine is administered at 200 mg/m²/day as a continuous IV infusion for 7 consecutive days 2
• Daunorubicin dosing at 60 mg/m² for 3 days is the evidence-based dose used in the pivotal RATIFY trial; higher doses (90 mg/m²) may improve outcomes in younger patients with adequate cardiac function, though this was not studied with concurrent midostaurin 1, 2
• Midostaurin 50 mg orally every 12 hours is added on days 8–21 of each induction and consolidation cycle 1, 2, 3
• This combination improved median overall survival from 25.6 months to 74.7 months (HR 0.78, P=0.009) in the RATIFY trial 1

Post-Induction Assessment

• Perform bone marrow aspirate and biopsy 14–21 days after induction start to assess response 2
• If significant residual disease persists without marrow hypoplasia, administer a second induction cycle using a 5+2 schedule (cytarabine × 5 days, anthracycline × 2 days) 2

Consolidation Therapy

• Patients achieving complete remission should receive 4 cycles of high-dose cytarabine (HiDAC) at 3 g/m² every 12 hours on days 1,3, and 5 with midostaurin 50 mg twice daily on days 8–21 1
• All patients with FLT3-ITD mutations should proceed to allogeneic hematopoietic cell transplantation (alloHCT) in first remission if eligible, regardless of NPM1 co-mutation status or FLT3 allelic ratio 3, 4, 5
• The 2022 European LeukemiaNet reclassified all FLT3-ITD AML as intermediate risk, making alloHCT the recommended consolidation approach 4

Post-Transplant Maintenance

• FLT3 inhibitor maintenance therapy after alloHCT reduces relapse risk, though optimal agent and duration remain under investigation 5, 6
• Gilteritinib is commonly used for post-transplant maintenance based on emerging data 5

---

Frontline Therapy for Older or Unfit Patients

For patients ≥60 years or those unfit for intensive chemotherapy, the preferred regimen is a triplet combination of hypomethylating agent (azacitidine or decitabine), venetoclax, and a FLT3 inhibitor (gilteritinib or quizartinib). 7, 8

Triplet Regimen Efficacy

• Composite complete remission (CR + CRi) rates reach 93% with HMA-venetoclax-FLT3 inhibitor triplets 8
• FLT3-ITD MRD negativity (sensitivity 0.005%) is achieved in 60% of patients after cycle 2 and 90% after cycle 4 8
• The 3-year overall survival for FLT3-ITD-mutated AML is 45% with triplet therapy, compared to 76% for FLT3-TKD mutations 8

Important Caveats for Triplet Therapy

• Baseline RAS pathway mutations predict poor outcomes (3-year OS 22% versus 63% without RAS mutations) 8
• FLT3 wild-type relapses account for 65% of relapses, with new RAS pathway mutations emerging in 24% of cases 8
• The American Society of Hematology 2025 guidelines strongly recommend incorporating FLT3 inhibitors into venetoclax-based regimens for appropriate patients 7

---

Relapsed or Refractory Disease

For relapsed or refractory FLT3-mutated AML, gilteritinib monotherapy is the FDA-approved standard, demonstrating superior outcomes compared to salvage chemotherapy. 5, 6

Gilteritinib in Relapsed Disease

• Gilteritinib is approved as monotherapy for relapsed/refractory FLT3-mutated AML based on the ADMIRAL study 6
• Overall response rates range from 21–43% with venetoclax-azacitidine combinations in the relapsed setting 9
• Median overall survival with hypomethylating agents in post-transplant relapse is approximately 6.7 months, with CR/CRi rates of 16.3% 9

Salvage Options and Prognosis

• For patients relapsing >5 months after first alloHCT who can achieve remission, a second allogeneic transplant offers the only realistic chance for long-term survival 9
• Without achieving remission, 5-year survival probability is <5% 9
• High-dose cytarabine-based intensive salvage is contraindicated in patients ≥60 years due to prohibitive toxicity (30-day mortality >14%) 9
• Clinical trial enrollment should be strongly pursued given poor outcomes with standard salvage approaches 9

---

Critical Monitoring and Resistance Patterns

MRD Assessment

• FLT3-ITD MRD monitoring by next-generation sequencing (sensitivity 0.005%) should be performed after cycle 2 and at end of treatment 3, 8
• MRD negativity correlates with improved relapse-free survival 8

Mechanisms of Resistance

• Resistance emerges through FLT3 point mutations, clonal selection, stromal protection, and off-target mutations in downstream signaling pathways 6, 10
• Sustained STAT5 phosphorylation, AXL upregulation, and CXCR4 signaling drive FLT3 inhibitor resistance 11
• FLT3 wild-type relapses are common (65% of relapses) and represent a major therapeutic challenge 8

---

Special Populations and Molecular Considerations

FLT3-TKD Mutations

• FLT3-TKD mutations (affecting 6–8% of patients) have better prognosis than FLT3-ITD, with 3-year OS of 76% versus 45% 5, 8
• The same midostaurin-based induction approach is recommended for both FLT3-ITD and FLT3-TKD mutations 1, 2

Co-Mutations

• NPM1 co-mutation no longer modifies risk stratification; all FLT3-ITD patients are considered intermediate risk requiring alloHCT 4
• IDH1/2 co-mutations may predict higher response rates to venetoclax combinations 9
• Consider adding ivosidenib or enasidenib to venetoclax-azacitidine in IDH-mutated cases 9